Level D· Scientific groundwork from lab and animal studiesAnimal StudyEurope PMCOpen access

Amniotic Membrane and Mesenchymal Stem Cell Coalescence for Islet Transplantation in Experimental Diabetes in Rats

Tiryaki M., Atmaca N., Pinarli F., Ozcan GB., Feyat MS., Mercan S.

Animal Study on Systemic / IV, published in J Tissue Eng Regen Med (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
J Tissue Eng Regen Med (2025)
Reported sample size
—
Source database
Europe PMC
PMID
41438817
PMCID
PMC12721394
DOI
10.1155/term/2645595

Abstract (original English)

Aims The aim of this study is to investigate the effects of islet cells and mesenchymal stem cells transferred together in the amniotic membrane (AM) in order to preserve the viability and functionality of islet cells on the success of islet transplantation in diabetes mellitus-induced rats. Methods A total of 80 male Wistar albino rats, aged 3.5-4 months, were included in this study. While 40 Wistar Albino rats were used for the process of islet cell isolation, 40 Wistar Albino rats were used to establish experimental groups. These rats were assigned to five experimental groups including eight rats in each. These groups were AM, amniotic membrane + mesenchymal stem cell (AM + MSC), amniotic membrane + islet cell (AM + IC), amniotic membrane + islet cell + mesenchymal stem cell (AM + IC + MSC), and sham groups. The study was concluded for 28 days. Results Although there was no significant difference between AM + IC and AM + IC + MSC groups in terms of mean blood glucose levels, both groups had statistically different values compared to the sham group. A significant difference was observed between the AM + IC and AM + IC + MSC groups in the c-peptide levels before and after transplantation. Immunohistochemical staining illustrated the presence of insulin-positive cells in both AM + IC and AM + IC + MSC groups. Moreover, BrDU (+) cells were determined in AM + IC and AM + IC + MSC

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
Islets of LangerhansAmnionMesenchymal Stem CellsAnimalsRatsRats, WistarDiabetes Mellitus, ExperimentalInsulinC-PeptideBlood Glucose

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research